Short answer
ADMA BIOLOGICS, INC. (ADMA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $141M (up 5.1% year over year) with net income of $50M.
Q3 2026 key financials · XBRL
- Revenue
- $141M
- +5.1% YoY · +13.4% QoQ
- Net income
- $50M
- +36.9% YoY · +31.9% QoQ
- Operating margin
- 48.0%
- Gross margin
- 70.8%
- EPS (diluted)
- $0.22
- +46.7% YoY · +37.5% QoQ
Source: XBRL data from the ADMA BIOLOGICS, INC. (ADMA) Q3 2026 10-Q on SEC EDGAR. USD.
ADMA BIOLOGICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $141.1M, up 5.1% YoY from $134.2M
- Gross margin 70.8% vs 56.3% YoY, net income $49.9M vs $36.4M
- Best performer ASCENIV revenue $124.7M, up 30.7%; BIVIGAM worst, $15.4M, down 35.2%
- Cash $124.6M vs $87.6M at December 31, 2025; nine-month operating cash flow $105.2M vs $14.8M
- Competitive IVIG pricing pressured BIVIGAM; inflation and supply-chain costs expected through Q4 2026 and 2027
Risk Factors
- Newly added securities litigation risk: July 10, 2026 class action and consolidated derivative proceedings alleging Exchange Act violations
- Most materially updated competitive risk: new FDA-approved IVIG competitors since 2H 2025 using aggressive pricing, rebates and extended payment terms
- Regulatory risk: FDA inspections could trigger warning letters, recalls, supply disruptions or manufacturing restrictions for ADMA and suppliers
- Operational risk: high-titer RSV plasma meeting specifications represents less than 10% of tested donor samples
- Financial risk: $197.2 million JPMorgan debt outstanding, maturing August 5, 2028, with substantially all assets pledged as collateral
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADMA BIOLOGICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.